Ventracor Limited Release: CE Mark Clinical Trial Results Released At European Launch Of VentrAssist

SYDNEY, Australia, 11 September 2006: The clinical results of the VentrAssist CE Mark Bridge Trial were presented at the European Association of Cardiothoracic Surgeons (EACTS) in Sweden today. The primary clinical end-point of the CE Mark Bridge Trial was cardiac transplant or continued transplant eligible at 154 days after a VentrAssist implant.

Back to news